Bridging the Gap in Lupus Research
Systemic Lupus Erythematosus (SLE or, more commonly, lupus) is a complex autoimmune disease, presenting unique challenges in clinical trials due to its chronic nature and multifactorial causes.
Patients with lupus experience diverse symptoms, highlighting the need for comprehensive information to understand its impact on individuals. However, current Lupus research relies on multiple questionnaires with differing symptom-scoring criteria impeding patient participation, compromising data quality, and influencing trial outcomes.
To overcome these challenges, Clinical ink has developed the electronic Lupus Assessment Suite (eLAS®), a purpose-built data capture and patient engagement solution designed specifically for SLE research.
Data Solutions to Improve Quality, Safety, and Efficiency
Leveraging Clinical ink’s Direct Data Capture solution (DDC), eLAS® simplifies the process of aggregating and analyzing multiple questionnaires with differing symptom scoring criteria. It facilitates information sharing between these forms, providing prompts for proper evaluation methods and real-time data validation.
Our solution streamlines data collection, eliminates duplication, enhances patient participation, improves data quality, and drives better outcomes in lupus clinical trials.
Powering Your SLE Trials
Using eSource and fit-for-purpose eLAS® technology, time-consuming manual activities and the errors of traditional paper methodologies are eliminated including managing, reconciling, and validating multiple questionnaires and forms.
Study teams and investigators realize significant benefits for clinical trial data analysis and collections: